Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$233M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Azoy Alexander | Aug 13, 2024 | Sell | 1,357 | $14.97 | $20,000 |
| Jarrett Jennifer | Mar 27, 2024 | Sell | 11,551 | $17.55 | $200,000 |
| Jarrett Jennifer | Mar 18, 2024 | Sell | 12,153 | $17.84 | $220,000 |
| Jarrett Jennifer | Mar 18, 2024 | Sell | 1,296 | $18.62 | $24,000 |
| Jarrett Jennifer | Feb 27, 2024 | Sell | 34,070 | $20.11 | $690,000 |
| Jaen Juan C. | Feb 27, 2024 | Sell | 23,132 | $20.1 | $460,000 |
| Jarrett Jennifer | Feb 26, 2024 | Sell | 24,555 | $20.07 | $490,000 |
| Jaen Juan C. | Feb 26, 2024 | Sell | 3,900 | $20.06 | $78,000 |
| GILEAD SCIENCES, INC. | Jan 29, 2024 | Buy | 15,238,095 | $21 | $320M |
| Goeltz II Robert C. | Jan 2, 2024 | Sell | 2,004 | $20 | $40,000 |
| Jaen Juan C. | Jan 2, 2024 | Sell | 6,975 | $20.09 | $140,000 |
| Jarrett Jennifer | Dec 22, 2023 | Sell | 21,521 | $17.76 | $380,000 |
| Azoy Alexander | Dec 1, 2023 | Sell | 282 | $14.95 | $4,200 |
| Jarrett Jennifer | Sep 22, 2023 | Sell | 21,369 | $19.99 | $430,000 |
| Jarrett Jennifer | Jul 28, 2023 | Sell | 45,000 | $20.25 | $910,000 |
| Azoy Alexander | Jul 3, 2023 | Sell | 1,018 | $20.41 | $21,000 |
| GILEAD SCIENCES, INC. | Jun 28, 2023 | Buy | 1,010,000 | $19.26 | $19M |
| Jarrett Jennifer | Jun 16, 2023 | Sell | 12,563 | $19.35 | $240,000 |
| Goeltz II Robert C. | Jun 7, 2023 | Sell | 4,049 | $20.04 | $81,000 |
| Jarrett Jennifer | Mar 16, 2023 | Sell | 8,729 | $16.81 | $150,000 |
| Jarrett Jennifer | Jan 27, 2023 | Sell | 1,600 | $23.52 | $38,000 |
| Jarrett Jennifer | Jan 26, 2023 | Sell | 300 | $23.56 | $7,100 |
What's the latest insider transaction for Arcus Biosciences?
The most recent insider transaction for Arcus Biosciences was conducted by Azoy Alexander, who sold 1,357 shares on August 13, 2024 at a price of $14.97 per share.
Which insider bought the most RCUS stock over the last two years?
GILEAD SCIENCES, INC. has bought the most RCUS stock in the last 2 years, with a total value of $339M.
Which insider has sold the most RCUS stock over the last two years?
Jarrett Jennifer has sold the most RCUS stock in the last 2 years, with a total value of $3.8M.
What is the total value of insider transactions for Arcus Biosciences (RCUS) in the last 2 years?
According to our estimates, the total value of insider transactions for Arcus Biosciences in the last 2 years is positive, amounting to $335M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Arcus Biosciences' market confidence?
Over the last 2 years, insider transactions for Arcus Biosciences have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
